September 19, 2013
Press release:
Mitsubishi Tanabe Pharma Corporation

Notice Regarding Completion of Acquisition of Shares of Medicago, Inc.,a Pharmaceutical Company Based in Canada, Which Has Becomea Subsidiary of Mitsubishi Tanabe Pharma
On September 18, 2013 (Canada time), Mitsubishi Tanabe Pharma (head office: Osaka, Japan,
President and Representative Director: Michihiro Tsuchiya) completed all of the procedures forthe acquisition of Medicago, Inc., a pharmaceutical company based in Canada, which wasannounced on July 12, 2013. As a result of this acquisition, Medicago has become a subsidiaryof Mitsubishi Tanabe Pharma. Going forward, Medicago will be operated as a joint venture
owned 60% by Mitsubishi Tanabe Pharma and 40% by Philip Morris Investments B.V. (Headoffice: Bergen op Zoom, the Netherlands).
1. Number of shares acquired, acquisition price, and percentage of ownership before and afteracquisition(1) Number of shares held before transfer
15,385,000 shares(Number of voting rights: 15,385,000)(Percentage of voting rights: 5.8%*)(2) Number of shares acquired
149,550,599 shares(Number of voting rights: 149,550,599)(3) Acquisition price
Medicago common stock: CAD173 million(4) Number of shares held after transfer
164,935,599 shares(Number of voting rights: 164,935,599)(Percentage of voting rights: 60.0%)* Mitsubishi Tanabe Pharma announced the percentage of voting rights as 6.0% on July 12, 2013. The latest
percentage was changed into 5.8% because of the exercise of warrants and stock options.

2. Future outlook
The influence of this acquisition on the consolidated results of Mitsubishi Tanabe Pharma iscurrently being determined, and notice will be provided promptly if it is determined that theCompany's results forecast needs to be revised.

3. Others
Mitsubishi Tanabe Pharma and Medicago made a joint release on September 18, 2013 (Canadatime) as per attached sheet.
EndPRESS RELEASEAPPROVED FOR PUBLIC RELEASE, DISTRIBUTION UNLIMITED
Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago.
Osaka, Japan and Quebec City, Canada – September 18, 2013 – Mitsubishi Tanabe Pharma
Corporation (TSE: 4508) (“Mitsubishi Tanabe Pharma” or “MTPC”) and Medicago Inc.
(TSX: MDG) announced today the completion of the previously announced acquisition of Medicago
Inc. by MTPC.
On September 18, 2013, 9284-9686 Québec Inc.,a subsidiary of MTPC, acquired all of theoutstanding common shares of Medicago, other than the common shares currently held by MTPCand Philip Morris Investments B.V. ("PMI") an affiliate of Philip Morris International Inc., pursuant tothe terms of an arrangement agreement made as of July 12, 2013. As a result, Medicago has
become jointly owned by MTPC (60%) and PMI (40%). Shareholders of Medicago, as of theeffective date of the arrangement, will be entitled to receive $1.16 per common share in cash, andholders of warrants and stock options will be entitled to receive a cash payment equal to thedifference between $1.16 and the exercise price of any warrant or stock option they hold.
The common shares of Medicago will be delisted from trading on the Toronto Stock Exchange, atthe end of trading on September 19, 2013.
“We are very pleased with the completion of this transaction and welcome Medicago to our group.
We look forward to working with Medicago’s management and employees as well as all thestakeholders to develop highly effective and competitive vaccines based on Medicago’s proprietary
technologies to contribute to the healthier lives of people around the world,” said Dr. Michihiro
Tsuchiya, President and Chief Executive Officer of MTPC.
“I would like to sincerely thank our employees, investors , partners and board members for theirimportant contribution leading to Medicago’s success, said Andy Sheldon, President and Chief
Executive Officer of Medicago. I would also like to thank our corporate partners MTPC and PMI for
their confidence in Medicago. We look forward to working closely with them to ensure ourinnovative, effective and cost efficient technology and products are brought to market”.
The acquisition of Medicago will be entirely satisfied with cash and sufficient funds have been
deposited with Computershare Investor Services Inc. to enable it to make payments to Medicago
shareholders, warrantholders and optionholders pursuant to the terms of the arrangementagreement. Letters of Transmittal have been mailed to registered shareholders of Medicago andare also available on SEDAR at www.sedar.com. The Letters of Transmittal explain how registered
Medicago shareholders can deposit and obtain payment for their shares. Registered Medicago
shareholders must return duly completed Letters of Transmittal to Computershare Investor
Services Inc. in order to receive the consideration to which they are entitled for their shares.
Non-registered shareholders should carefully follow the instructions from the broker or otherfinancial intermediary that holds shares on their behalf.
About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel vaccines andtherapeutic proteins to address a broad range of infectious diseases worldwide. Medicago iscommitted to providing highly effective and competitive vaccines and therapeutic proteins based on
its proprietary VLP and manufacturing technologies. Medicago is a worldwide leader in thedevelopment of VLP vaccines using a transient expression system which produces recombinantvaccine antigens in plants. This technology has potential to offer more potent vaccines with speed
and cost advantages over competitive technologies, enabling the development of a vaccine fortesting in approximately one month after the identification and reception of genetic sequences froma pandemic strain. This production time frame has the potential to allow vaccination of thepopulation before the first wave of a pandemic, and supply large volumes of vaccine antigens to theworld market. Medicago also intends to expand development into other areas such as biosimilars
and biodefense products where the benefits of our technologies can make a significant difference.
Additional information about Medicago is available at www.medicago.com.
About Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma is a research-driven pharmaceutical company based in Japan,
specializing in research, development and marketing of globally competitive pharmaceuticalproducts focused on the field of autoimmune disease, diabetes and kidney disease, and CNS
disease. Mitsubishi Tanabe Pharma contributes to the healthier lives of people around the world
through the creation of pharmaceuticals that respond to unmet medical needs. Additional
information about MTPC is available at http://www.mt-pharma.co.jp/e.
Forward Looking Statements
This news release includes certain forward-looking statements or forward-looking information forthe purposes of applicable securities laws and such statements and information are based uponcurrent expectations, which involve risks and uncertainties associated with Medicago’s businessand the environment in which the business operates. Any statements contained herein that are notstatements of historical facts may be deemed to be forward-looking, including those identified by
the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, and similar
expressions to the extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago’s current expectations regarding future
results or events. These forward-looking statements are subject to a number of risks anduncertainties that could cause actual results or events to differ materially from current expectations,
including the matters discussed under “Risk Factors and Uncertainties” in Medicago’s AnnualInformation Form filed on March 28, 2013, with the regulatory authorities. Medicago assumes noobligation to update the forward-looking statements, or to update the reasons why actual results
could differ from those reflected in the forward-looking statements.

For further information:
Medicago Inc.
Andy Sheldon
President and CEO(418) 658-9393

Medicago Inc.
Christina Cameron
Investor Relations
cameronc@medicago.com(418) 658-9393 ext.156

For inquiries regarding Mitsubishi Tanabe Pharma Corporation:
Mitsubishi Tanabe Pharma Corporation
Yoshihisa Sasou
General Manager
Corporate Communications Department+81-6-6205-5110